Temozolomide (TMZ) is used to treat primary brain tumors and non-small cell lung cancer (NSCLC) brain metastases, yet therapeutic efficacy is often limited by the DNA repair enzyme O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT). The gene discussed is MGMT; the disease is non-small cell lung carcinoma.